One of my boys has been hospitalized twice in the last 18 months for a respiratory syncytial virus (RSV) infection. For most people, RSV is considered a common cold, but for people with immunodeficiencies or compromised pulmonary function, it can be deadly. While doing my research on the virus and potential ways to protect against it (there is currently no approved vaccine), I came across an interesting little company called ADMA Biologics (NASDAQ:ADMA). The company is small, illiquid, and not on a lot of radar screens, but there are quite a few reasons to take a closer look (ranked from most significant to least):
1) ADMA's lead product, RI-002, is an improved intravenous immunoglobulin (IVIG) product with an...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|